| Date | Title | Description |
| 26.11.2024 | Roche приобретает производителя клеточной терапии Poseida Therapeutics за $1,5 млрд | «Это приобретение будет способствовать появлению ряда потенциально «первых и лучших в своем классе методов лечения» в области онкологии, иммунологии и неврологии, что позволит Roche занять уникальное положение в новой области готовых методо... |
| 30.08.2021 | Poseida Therapeutics Announces FDA Clearance of Investigational New Drug Application for P-BCMA-ALLO1, an Allogeneic CAR-T Candidate for Relapsed/Refractory Multiple Myeloma | |
| 02.06.2021 | Poseida Therapeutics Announces Virtual 2021 Annual Meeting of Stockholders | |
| 06.05.2021 | Poseida Therapeutics Announces Key Additions to Immuno-Oncology Scientific Advisory Board | |
| 23.03.2021 | Poseida Therapeutics Announces Carl June, M.D., to Chair Immuno-Oncology Scientific Advisory Board | |
| 02.11.2020 | Poseida Therapeutics Announces Clinical Hold Lifted on Phase I Autologous CAR-T Study in Prostate Cancer | |
| 21.10.2020 | Poseida Therapeutics and TScan Therapeutics Announce Research Collaboration and License Agreement to Explore Developing Allogeneic T Cell Receptor Therapies for the Treatment of COVID-19 | |
| 23.09.2020 | Healthcare VC Firm Longitude Capital Closes $585M Fund | What You Should Know:
– Healthcare venture capital firm Longitude Capital announces the close of its $585M Longitude Venture Partners IV, L.P. (“LVP4”) fund to invest in transformative healthcare companies.
– LVP4 will invest opportunistica... |
| 23.09.2020 | Longitude Capital Raises $585 Million Fund to Invest in Transformative Healthcare Companies | - Longitude Venture Partners IV will build on the Firm’s commitment to improve clinical outcomes, enhance patient quality of life, and drive efficiency in healthcare delivery -
- In 2020 to date, Longitude portfolio companies announced 4 IP... |
| 13.07.2020 |
Poseida Therapeutics Debuts In IPO
| San Diego-based biopharmaceuticals firm Poseida Therapeutics successfully made it to the public markets with an IPO on Friday, raising $224M in an offering on the Nasdaq Global Select Market. The company, which now trades as PSTX, priced it... |
| 26.06.2020 | Poseida Therapeutics has closed a $110M Series D while it prepares for its expected $115M IPO | - |
| 25.06.2020 | Poseida Therapeutics Raises $110 Million in Series D Financing | SAN DIEGO, June 25, 2020 — Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to utilizing proprietary gene engineering platform technologies to create next generation cell and gene therapeutics with the capaci... |
| 25.06.2020 | Poseida Therapeutics Raises $110M To Advance Gene Therapeutics | 8 Shares Email Facebook Twitter LinkedIn
A year after closing its largest raise to date, biopharmaceutical company Poseida Therapeutics Inc. announced the closing of a $110 million Series D financing round.
Subscribe to the Crunchbase Daily... |
| 25.06.2020 | Poseida Therapeutics Raises $110M in Series D Financing | Poseida Therapeutics, Inc., a San Diego, CA-based clinical-stage biopharmaceutical company dedicated to creating cell and gene therapeutics with the capacity to cure, closed a Series D financing round, raising $110m.
The round was led by fu... |
| 25.06.2020 | Poseida Therapeutics Lands $110M Series D |
SAN DIEGO, CA, Poseida Therapeutics today announced the closing of a Series D financing round, raising $110 million.
>> Click here for more funding data on Poseida Therapeutics
>> To export Poseida Therapeutics funding data ... |
| 25.06.2020 |
Poseida Therapeutics Finds $110M More
| San Diego-based biopharmaceuticals developer Poseida Therapeutics has raised $110M more in funding, in its Series D round, the company announced this morning. According to the company, the financing was led by led by funds advised by Fideli... |
| 14.05.2019 | Poseida Therapeutics, Be The Match BioTherapies team up on CAR-T logistics | Poseida plans to start a Phase II study of P-BCMA-101, a CAR-T therapy that targets the antigen BCMA for multiple myeloma, in the first half of this year. Later in the year, it also plans to file an application with the Food and Drug Admini... |
| 14.05.2019 | Takeda forecasts $1.7B loss after Shire integration; Flagship's preclinical biotech Axcella closes IPO with $71M+ haul | → Takeda’s $TAK first set of financial results since consummating its $62 billion acquisition of Shire is in, and it’s giving analysts a negative surprise. Citing costs for integrating the Ireland-based Shire, the Japa... |
| 28.04.2019 | Poseida Therapeutics Raises $142M in Series C Round | Eric Ostertag Poseida CEO
Poseida Therapeutics raised $142 million in a Series C round to advance therapies that alter immune cells to kill cancer.
San Diego-based Poseida is working in CAR-T therapy, in which a patient’s T cells are engine... |
| 22.04.2019 | Poseida Therapeutics Snares $142M in Series C |
SAN DIEGO, CA, Clinical-stage biopharmaceutical company has raised $142 million in Series C.
>> Click here for more funding data on Poseida Therapeutics
>> To export Poseida Therapeutics funding data to PDF and Excel, click ... |
| 22.04.2019 | Poseida Therapeutics Closes $142M Series C Financing | Poseida Therapeutics Inc., a San Diego, CA-based clinical-stage biopharmaceutical company leveraging proprietary non-viral gene engineering technologies to create life-saving therapeutics, closed a $142m Series C financing.
The round was le... |
| 22.04.2019 | Poseida raises $142M in Series C round to advance multiple myeloma CAR-T, preclinical cell therapies | The company’s lead product candidate is P-BCMA-101, an autologous CAR-T that targets the BCMA antigen in the blood cancer multiple myeloma. It is currently in a registration-directed Phase II clinical trial that is recruiting patients.
“We ... |
| 22.04.2019 | Vaping Startup Pax Labs Raises $420 Million in Funding: Term Sheet for Monday, April 22 | A UNICORN THAT VAPES
We’ve got another vaping unicorn.
Paid Content You can't secure what you can't see From ExtraHop
You may wonder — is e-cigarette vaping startup Juul somehow involved in this? Not really, but it does have connections. Ju... |
| 22.04.2019 | CAR-T maker Poseida forgoes IPO, hauls in $142M series C instead
W h i t e p a p e r
Vital Precision for Cost Reduction, QA, and Regulatory Compliance | CAR-T developer Poseida Therapeutics has put the kibosh on its IPO plans for now and is settling instead for a $142 million series C round, with more than half of the money coming from cell and gene therapy devotee Novartis.
The Big Pharma ... |
| 22.04.2019 | Poseida Therapeutics Raises $142 Million In Series C Financing | SAN DIEGO, April 22, 2019 — Poseida Therapeutics Inc., a clinical-stage biopharmaceutical company leveraging proprietary non-viral gene engineering technologies to create life-saving therapeutics, today announced closing of a Series C finan... |
| 22.04.2019 |
Poseida Therapeutics Finds $142M
| San Diego-based Poseida Therapeutics, a biopharmaceuticals startup developing non-viral gene engineering technology, has raised $142M in a Series C funding, the company said on Monday. According to the company, the funding was led by Novart... |
| 22.04.2019 | CAR-T maker Poseida forgoes IPO, hauls in $142M series C instead | CAR-T developer Poseida Therapeutics has put the kibosh on its IPO plans for now and is settling instead for a $142 million series C round, with more than half of the money coming from cell and gene therapy devotee Novartis.
The Big Pharma ... |
| 10.04.2018 | Poseida Therapeutics Raises $30.5M to Further Develop Cancer Treatments | Poseida Therapeutics Inc., a San Diego-based biotechnology company using gene editing to develop medicines, said it raised $30.5 million in a Series B round led by Longitude Capital, a health care venture capital firm in Silicon Valley.
As ... |
| 05.04.2018 | Poseida Therapeutics Hauls in $30.5M Series B |
SAN DIEGO, CA, Poseida Therapeutics has raised $30.5 million in an oversubscribed Series B financing round, led by Longitude Capital.
>> Click here for more funding data on Poseida Therapeutics
>> To export Poseida Therapeut... |
| 05.04.2018 | Term Sheet — Thursday April 5 | GOT MONEY
Good morning, Term Sheet readers.
Paid Content How can you protect what you can't see? From ExtraHop
The new company is being described as “a mentorship engine that partners with founders to solve core businesses challenges.” In r... |
| 03.04.2018 | Poseida Raises $30.5M in Series B Financing | Poseida Therapeutics, Inc., a San Diego-based company translating gene engineering technologies into cell therapies, raised $30.5 million in Series B financing.
The round was led by Longitude Capital, with participation from new investors V... |
| 29.12.2015 | Daily funding roundup - December 29, 2015 | Poseida Therapeutics secured $23M; Bellhops, Inc raised $13.5M; PastBook received $380k financing
PastBook, an Amsterdam based social media memory preservation platform, raised an additional $380,000 in seed funding. Backers included variou... |
| 20.12.2015 | Poseida Therapeutics Closes Series A Financing | Poseida Therapeutics, Inc., a La Jolla, CA-based human therapeutics company, closed a Series A financing.
The round was led by Malin Corporation plc., an Irish-based global life sciences company, which will contribute up to $30m. The remain... |
| - | Poseida Therapeutics, Be The Match BioTherapies team up on CAR-T logistics | A company developing CAR-T therapies for multiple myeloma and prostate cancer is teaming up with a firm with the aim of improving often complex logistics that come with the cell therapies.
Minneapolis-based Be The Match BioTherapies said Tu... |
| - | Poseida raises $142M in Series C round to advance multiple myeloma CAR-T, preclinical cell therapies | A Swiss drugmaker that markets one of the two approved CAR-T cell therapies has led the latest financing of a company developing CAR-Ts of its own.
San Diego-based Poseida Therapeutics said Monday that it had closed a $142 million Series C ... |
